EO 1022
Alternative Names: EO-1022; EO122Latest Information Update: 06 May 2025
At a glance
- Originator Elevation Oncology
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 May 2025 Pharmacodynamics data from a preclinical studies in Solid tumors released by Elevation Oncology
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Mar 2025 Elevation Oncology plans a clinical trial for Solid tumours in 2026